Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children.
Pediatr Infect Dis J
; 28(9): 835-7, 2009 Sep.
Article
em En
| MEDLINE
| ID: mdl-19636278
ABSTRACT
Previously healthy children hospitalized with respiratory syncytial virus (RSV) received motavizumab (3, 15, or 30 mg/kg intravenously), an RSV-specific monoclonal antibody, or placebo. Safety, tolerability, motavizumab concentrations, and immunogenicity were assessed. Cultivatable RSV in the upper respiratory tract was significantly reduced with motavizumab compared with placebo day 1 post-treatment. No adverse events were considered motavizumab-related by site investigators.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antivirais
/
Vírus Sincicial Respiratório Humano
/
Infecções por Vírus Respiratório Sincicial
/
Anticorpos Monoclonais
Idioma:
En
Ano de publicação:
2009
Tipo de documento:
Article